

PIPELINE REPORT

Generic Drugs

February 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Advair Diskus	salmeterol / fluticasone	GlaxoSmithKline	2018	COPD	High
Astagraf XL	tacrolimus	Astellsa	2018	Transplant	Low
AzaSite	azithromycin drops	Inspire	2018-2019	Eye Infections	Moderate
Byetta	exenatide injection	AstraZeneca	2018	Diabetes	Low
Durezol	difluprednate	Sirion	2018-2019	Eye Inflammation	Moderate
Fentora	fentanyl buccal tablet	Teva	2018-2019	Pain/Inflammation	Moderate
Flector	diclofenac epolamine	INST Biochem	2018-2019	Pain/Inflammation	Moderate
Forfivo XL	bupropion XL	Edgemont	2018	Depression	Low
Ganirelix	ganirelix acetate	Organon	2018	Infertility	Moderate
Kaletra Tablets	lopinvir	AbbVie	2018	HIV	High
Letairis	ambrisentan	Gilead	2018-2019	Pulmonary Hypertension	High
MoviPrep	polyethylene glycol	Salix	4Q 2018	Constipation	Low
Potiga	ezogabine	GlaxoSmithKline	2018-2020	Seizures	Moderate
Prestalia	amlodipine / perindopril	Sympld	2018-2019	High Blood Pressure/ Heart Disease	Low
Remodulin	treprostinil	United Therapeutics	4Q 2018	Pulmonary Hypertension	Moderate
Renagel	sevelamer	Genzyme	2018-2021	Endocrine Disorders	Low
Rescula	unoprostone isopropyl	Sucampo	2018-2021	Glaucoma	Low
Restasis	cyclosporine	Allergan	2018-2019	Dry Eye Disorder	High
Samsca	tolvaptan	Otsuka	2018-2019	Endocrine Disorders	Moderate
Sprix	ketorolac tromethamine	Egalet	2018	Inflammatory Conditions	Low
Suprenza	phentermine	Citius Pharmaceuticals	2018	Weight Loss	Low
Travatan Z	travoprost	Alcon	2018-2019	Glaucoma	Moderate
Zortress	everolimus	Novartis	2018-2021	Cancer	Moderate
Zyclara	imiquimod cream	MEDICIS	Jan-19	Skin Conditions	Low

PIPELINE REPORT

Generic Drugs

February 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Tekturna	aliskiren hemifumarate	Novartis	Mar-19	High Blood Pressure/ Heart Disease	Low
Symlin	pramlintide acetate	Amylin	Mar-19	Diabetes	Low
Faslodex	fulvestrant	AstraZeneca	Mar-19	Cancer	Moderate
Vesicare	solifenacin	Astellas	Apr-19	Urinary Disorders	High
Cetrotide	cetorelix	Serono	Apr-19	Infertility	Moderate
Firazyr	icatibant acetate	Shire	Jul-19	Hereditary Angioedema	Moderate
Relistor	methylnaltrexone bromide	Salix	Jul-19	Constipation	Low
Thalomid	thalidomide	Celgene	Aug-19	Cancer	Moderate
Jadenu	deferasirox	Novartis	Oct-19	Iron Toxicity	Moderate
Synribo	omacetaxine	IVAX	Nov-19	Cancer	Low
Delzicol	mesalamine	Warner Chilcott	2Q 2018	Inflammatory Conditions	Moderate
Diclegis	doxylamine / pyridoxine	Duchesnay	2019-2020	Nausea / Vomiting	High
Forteo	teriparatide	Lilly	2H 2019	Osteoporosis	High
Tarceva	erlotinib	OSI Pharma	2019	Cancer	High
Tracleer	bosentan	Actelion	2019	Pulmonary Hypertension	Moderate
Noxafil Suspension	posaconazole	Schering-Plough	Jan-20	Fungal Infections	High
Qudexy XR	topiramate ER	Upsher-Smith	Mar-19	Seizures	Low
Eligard	leuprolide acetate	Sanofi	Mar-19	Cancer	Moderate
Dulera	formoterol / mometasone	Merck	May-19	Asthma	High
Saphris	asenapine	Organogenesis Inc	1H 2020	Mental Disorders	Moderate
Pomalyst	pomalidomide	Celgene	Aug-20	Cancer	High
Tykerb	lapatinib	GlaxoSmithKline	Sep-20	Cancer	Moderate
Chantix	varenicline	Pfizer	2020-2022	Smoking Cessation	High
Dexilant	dexlansoprazole	Takeda	2020-2023	Heartburn / Ulcer	High
Kuvan	sapropterin hydrochloride	Biomarin	2020-2021	Endocrine Disorders	Low

PIPELINE REPORT

Generic Drugs

February 2019



BRAND NAME	GENERIC NAME	MANUFACTURER	ESTIMATED LAUNCH DATE*	THERAPEUTIC USE	POTENTIAL IMPACT
Latuda	lurasidone	Sunovion	2020-2022	Mental Disorders	High
Revlimid	lenalidomide	Celgene	2020-2023	Cancer	Moderate
Toviaz	fesoterodine	Pfizer	2020-2021	Urinary Disorders	High
Uloric	febuxostat	Takeda	2020-2022	Gout	Moderate
Viibryd	vilazodone	Forest	2020-2021	Depression	Moderate
Xyrem	sodium oxybate	Jazz	2020-2023	Sleep Disorders	High
Amitiza	lubiprostone	Sucampo	Jan-21	Constipation	Moderate
Northera	droxidopa	Lundbeck	Feb-21	Low Blood Pressure	Low
Tecfidera	dimethyl fumarate	Biogen	May-21	Multiple Sclerosis	High
Aptiom	eslicarbazepine	Sunovion	Jun-21	Seizures	Low
Atripla	efavirenz / emtricitabine / tenofovir	Gilead	1H 2021	HIV	Moderate
Truvada	emtricitabine / tenofovir	Gilead	1H 2021	HIV	Moderate
Selzentry	maraviroc	Pfizer	Aug-21	HIV	Moderate
Sutent	sunitinib	Pfizer	Aug-21	Cancer	High
Bystolic	nebivolol	Forest	Sep-21	High Blood Pressure/ Heart Disease	Moderate
Cayston	aztreonam	Gilead	Dec-21	Cystic Fibrosis	Moderate
Bepreve	bepotastine	Ista	2021	Eye Disorders	Low
Onexton Gel	benzoyl peroxide / clindamycin	Valeant	2021-2022	Acne	Moderate
Perforomist	formoterol	Dey	2021-2022	Asthma	Low
Pradaxa	dabigatran etexilate	Boehringer Ingelheim	4Q 2021	Anticoagulant	Moderate

*Estimated launch dates are subject to change at any time due to legal proceedings, exclusivity, timing of FDA approvals, additional patents, etc.

References:

- FDA Electronic Orange Book. Available at: <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed June 7, 2017.
- Drugs@FDA. Available at: <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>. Accessed June 7, 2017.